Ken Griffin Castle Biosciences Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $536,382 - $751,410	29,700 Added 450.0%	36,300 $804,000
Q4 2023 Feb 14, 2024	SELL	$12.19 - $22.43 $525,389 - $966,733	-43,100 Reduced 86.72%	6,600 $142,000
Q3 2023 Nov 14, 2023	BUY	$13.28 - $20.3 $555,104 - $848,540	41,800 Added 529.11%	49,700 $839,000
Q2 2023 Aug 14, 2023	SELL	$11.66 - $26.0 $57,134 - $127,400	-4,900 Reduced 38.28%	7,900 $108,000
Q1 2023 May 15, 2023	SELL	$19.47 - $28.49 $202,488 - $296,296	-10,400 Reduced 44.83%	12,800 $290,000

Q4 2022 Feb 14, 2023	SELL	$18.08 - $30.0 $106,671 - $177,000	-5,900 Reduced 20.27%	23,200 $546,000
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $655,041 - $998,712	29,100 New	29,100 $759,000

162

25.3M

82.2K

150K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $572M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.